Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperparathyroidism, Secondary | 31 | 2022 | 70 | 7.630 |
Why?
|
Hyperphosphatemia | 19 | 2023 | 21 | 7.350 |
Why?
|
Renal Insufficiency, Chronic | 31 | 2023 | 350 | 7.090 |
Why?
|
Renal Dialysis | 47 | 2023 | 355 | 7.060 |
Why?
|
Kidney Failure, Chronic | 41 | 2023 | 509 | 5.790 |
Why?
|
Ferric Compounds | 14 | 2023 | 38 | 4.620 |
Why?
|
Sucrose | 13 | 2023 | 64 | 4.500 |
Why?
|
Parathyroid Hormone | 44 | 2020 | 218 | 4.480 |
Why?
|
Phosphorus | 23 | 2023 | 118 | 3.930 |
Why?
|
Ergocalciferols | 15 | 2020 | 38 | 3.470 |
Why?
|
Vitamin D Deficiency | 11 | 2020 | 103 | 3.290 |
Why?
|
Phosphates | 13 | 2023 | 160 | 3.210 |
Why?
|
Vitamin D | 17 | 2020 | 261 | 3.160 |
Why?
|
Chelating Agents | 11 | 2023 | 69 | 2.880 |
Why?
|
Bone and Bones | 19 | 2015 | 265 | 2.820 |
Why?
|
Chronic Kidney Disease-Mineral and Bone Disorder | 14 | 2019 | 23 | 2.590 |
Why?
|
Kidney Diseases | 17 | 2010 | 418 | 2.580 |
Why?
|
Bone Diseases, Metabolic | 9 | 2018 | 33 | 2.570 |
Why?
|
Calcitriol | 15 | 2020 | 174 | 2.470 |
Why?
|
Kidney Transplantation | 14 | 2020 | 849 | 2.460 |
Why?
|
Calcium | 31 | 2016 | 1156 | 2.340 |
Why?
|
Lanthanum | 7 | 2023 | 16 | 2.260 |
Why?
|
Vitamins | 6 | 2016 | 81 | 2.050 |
Why?
|
Bone Diseases | 7 | 2020 | 54 | 1.950 |
Why?
|
Bone Density | 17 | 2018 | 209 | 1.660 |
Why?
|
beta 2-Microglobulin | 11 | 2008 | 24 | 1.650 |
Why?
|
Glomerular Filtration Rate | 14 | 2021 | 384 | 1.530 |
Why?
|
Calcifediol | 4 | 2019 | 21 | 1.520 |
Why?
|
Fibroblast Growth Factors | 7 | 2020 | 80 | 1.500 |
Why?
|
Minerals | 3 | 2018 | 22 | 1.420 |
Why?
|
Drug Combinations | 13 | 2023 | 224 | 1.310 |
Why?
|
Humans | 133 | 2023 | 86601 | 1.230 |
Why?
|
Sevelamer | 6 | 2020 | 6 | 1.150 |
Why?
|
Amyloidosis | 8 | 2008 | 115 | 1.080 |
Why?
|
Calciphylaxis | 2 | 2016 | 4 | 1.050 |
Why?
|
Receptors, Calcitriol | 4 | 2016 | 129 | 0.950 |
Why?
|
Osteoporosis | 7 | 2011 | 121 | 0.940 |
Why?
|
Naphthalenes | 5 | 2010 | 45 | 0.930 |
Why?
|
Calcimimetic Agents | 4 | 2020 | 5 | 0.900 |
Why?
|
Middle Aged | 52 | 2021 | 25017 | 0.880 |
Why?
|
Calcium Channel Agonists | 5 | 2007 | 13 | 0.850 |
Why?
|
Aged | 41 | 2021 | 18402 | 0.820 |
Why?
|
Isoquinolines | 1 | 2021 | 72 | 0.800 |
Why?
|
Intestinal Absorption | 1 | 2021 | 124 | 0.790 |
Why?
|
Male | 63 | 2021 | 40956 | 0.790 |
Why?
|
Parathyroidectomy | 3 | 2022 | 78 | 0.770 |
Why?
|
Peritoneal Dialysis | 6 | 2017 | 32 | 0.760 |
Why?
|
Bone Resorption | 5 | 2008 | 41 | 0.760 |
Why?
|
Kidney Cortex | 2 | 2019 | 33 | 0.730 |
Why?
|
Fractures, Bone | 5 | 2007 | 131 | 0.710 |
Why?
|
Female | 61 | 2021 | 44507 | 0.710 |
Why?
|
Intestine, Small | 1 | 2021 | 303 | 0.700 |
Why?
|
Polyamines | 3 | 2014 | 32 | 0.690 |
Why?
|
Sulfonamides | 1 | 2021 | 300 | 0.690 |
Why?
|
Bone Remodeling | 4 | 2023 | 24 | 0.670 |
Why?
|
Treatment Outcome | 20 | 2019 | 7988 | 0.660 |
Why?
|
Kidney Tubules | 1 | 2019 | 94 | 0.650 |
Why?
|
Femoral Neck Fractures | 1 | 2018 | 11 | 0.640 |
Why?
|
Chronic Disease | 12 | 2010 | 970 | 0.630 |
Why?
|
Quality of Life | 3 | 2023 | 1583 | 0.620 |
Why?
|
Fracture Fixation, Internal | 1 | 2018 | 66 | 0.610 |
Why?
|
Biomarkers | 14 | 2023 | 1718 | 0.610 |
Why?
|
Transplant Recipients | 1 | 2018 | 122 | 0.610 |
Why?
|
Hypercalcemia | 5 | 2014 | 59 | 0.610 |
Why?
|
Kidney | 9 | 2022 | 1241 | 0.590 |
Why?
|
Hyperparathyroidism | 1 | 2016 | 67 | 0.580 |
Why?
|
Aluminum | 12 | 1995 | 22 | 0.580 |
Why?
|
Skull | 9 | 2008 | 249 | 0.570 |
Why?
|
Bone Density Conservation Agents | 4 | 2016 | 45 | 0.550 |
Why?
|
Adult | 36 | 2023 | 25640 | 0.540 |
Why?
|
Nephrology | 1 | 2016 | 45 | 0.540 |
Why?
|
Immunosuppressive Agents | 6 | 2020 | 977 | 0.540 |
Why?
|
Disease Progression | 9 | 2021 | 1531 | 0.510 |
Why?
|
Double-Blind Method | 10 | 2019 | 1823 | 0.510 |
Why?
|
Iron | 4 | 2022 | 164 | 0.490 |
Why?
|
Calcinosis | 3 | 2013 | 224 | 0.490 |
Why?
|
Oxygen | 4 | 2021 | 726 | 0.480 |
Why?
|
Skin Ulcer | 1 | 2013 | 25 | 0.470 |
Why?
|
Osteoblasts | 4 | 2001 | 95 | 0.460 |
Why?
|
Time Factors | 16 | 2021 | 5209 | 0.440 |
Why?
|
Sodium Bicarbonate | 2 | 2023 | 10 | 0.430 |
Why?
|
Osteoclasts | 4 | 2013 | 33 | 0.410 |
Why?
|
Osteogenesis | 6 | 2017 | 242 | 0.410 |
Why?
|
Glycation End Products, Advanced | 3 | 2013 | 13 | 0.400 |
Why?
|
Calcification, Physiologic | 3 | 2007 | 33 | 0.390 |
Why?
|
Plaque, Atherosclerotic | 1 | 2011 | 54 | 0.390 |
Why?
|
Pain | 1 | 2013 | 391 | 0.390 |
Why?
|
Furosemide | 3 | 2019 | 33 | 0.380 |
Why?
|
Risk Factors | 13 | 2015 | 5416 | 0.380 |
Why?
|
Alkaline Phosphatase | 6 | 2015 | 132 | 0.370 |
Why?
|
Magnetic Resonance Imaging | 5 | 2021 | 3352 | 0.350 |
Why?
|
Creatinine | 4 | 2021 | 338 | 0.350 |
Why?
|
Oleanolic Acid | 2 | 2019 | 13 | 0.340 |
Why?
|
Drug Interactions | 2 | 2021 | 248 | 0.330 |
Why?
|
Cyclosporine | 3 | 2004 | 234 | 0.330 |
Why?
|
Pancreas Transplantation | 3 | 2004 | 103 | 0.320 |
Why?
|
Aged, 80 and over | 10 | 2019 | 6501 | 0.320 |
Why?
|
Biopsy | 4 | 2009 | 1161 | 0.310 |
Why?
|
Protein Kinase C | 2 | 1999 | 270 | 0.300 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2020 | 294 | 0.300 |
Why?
|
Prognosis | 7 | 2018 | 3674 | 0.290 |
Why?
|
Coronary Artery Disease | 1 | 2011 | 350 | 0.290 |
Why?
|
Administration, Oral | 5 | 2020 | 684 | 0.290 |
Why?
|
Retrospective Studies | 7 | 2023 | 8475 | 0.290 |
Why?
|
Hip Fractures | 1 | 2007 | 45 | 0.290 |
Why?
|
Metabolic Diseases | 1 | 2007 | 48 | 0.280 |
Why?
|
Animals | 32 | 2021 | 26581 | 0.280 |
Why?
|
Interleukin-6 | 3 | 2008 | 256 | 0.280 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 827 | 0.280 |
Why?
|
Spinal Fractures | 1 | 2007 | 75 | 0.280 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 116 | 0.270 |
Why?
|
Severity of Illness Index | 6 | 2021 | 1801 | 0.260 |
Why?
|
Prospective Studies | 8 | 2022 | 4210 | 0.240 |
Why?
|
Canada | 3 | 2015 | 204 | 0.240 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 1621 | 0.240 |
Why?
|
Hospitalization | 2 | 2007 | 848 | 0.240 |
Why?
|
Carbonates | 1 | 2023 | 5 | 0.240 |
Why?
|
Azathioprine | 1 | 2004 | 125 | 0.230 |
Why?
|
Biological Transport | 2 | 2021 | 396 | 0.220 |
Why?
|
Tablets | 2 | 2023 | 118 | 0.220 |
Why?
|
Medication Adherence | 3 | 2019 | 129 | 0.220 |
Why?
|
Niacinamide | 2 | 2020 | 116 | 0.220 |
Why?
|
Diabetic Nephropathies | 3 | 2019 | 248 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 2600 | 0.210 |
Why?
|
Interleukin-1 | 2 | 2008 | 71 | 0.210 |
Why?
|
Albuminuria | 2 | 2021 | 153 | 0.210 |
Why?
|
Practice Guidelines as Topic | 5 | 2019 | 1034 | 0.210 |
Why?
|
Sodium-Hydrogen Exchanger 3 | 1 | 2021 | 32 | 0.210 |
Why?
|
Glucose | 2 | 2002 | 638 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2007 | 1961 | 0.200 |
Why?
|
Phosphorus, Dietary | 1 | 2020 | 4 | 0.190 |
Why?
|
Iron Overload | 1 | 2020 | 6 | 0.190 |
Why?
|
Kidney Medulla | 1 | 2021 | 80 | 0.190 |
Why?
|
Diet | 2 | 2023 | 443 | 0.190 |
Why?
|
Inflammation | 2 | 2020 | 920 | 0.190 |
Why?
|
Cholecalciferol | 1 | 2020 | 35 | 0.190 |
Why?
|
United States | 9 | 2022 | 6665 | 0.180 |
Why?
|
Cognition Disorders | 2 | 1994 | 236 | 0.180 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 683 | 0.180 |
Why?
|
Bone Substitutes | 1 | 1999 | 9 | 0.170 |
Why?
|
Anemia | 1 | 2020 | 128 | 0.170 |
Why?
|
Biomedical Engineering | 1 | 1999 | 20 | 0.170 |
Why?
|
Mice | 13 | 2017 | 11352 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 1373 | 0.170 |
Why?
|
Cytokines | 4 | 2012 | 776 | 0.170 |
Why?
|
Bone Regeneration | 1 | 1999 | 52 | 0.170 |
Why?
|
Absorbable Implants | 1 | 1999 | 34 | 0.170 |
Why?
|
Waist Circumference | 1 | 2018 | 20 | 0.170 |
Why?
|
Receptors, Immunologic | 2 | 2013 | 135 | 0.170 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 136 | 0.170 |
Why?
|
Drug Therapy, Combination | 3 | 2020 | 894 | 0.170 |
Why?
|
Russia | 2 | 2015 | 25 | 0.170 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 1169 | 0.170 |
Why?
|
Australia | 2 | 2015 | 99 | 0.160 |
Why?
|
Government Regulation | 1 | 2018 | 49 | 0.160 |
Why?
|
Diabetes Mellitus | 2 | 2012 | 806 | 0.160 |
Why?
|
Cell Hypoxia | 1 | 2019 | 164 | 0.160 |
Why?
|
Oxygen Consumption | 1 | 2019 | 239 | 0.160 |
Why?
|
Surgeons | 1 | 2022 | 238 | 0.160 |
Why?
|
Acid Phosphatase | 3 | 2008 | 33 | 0.160 |
Why?
|
Mice, Inbred Strains | 4 | 2008 | 307 | 0.160 |
Why?
|
Kidney Function Tests | 1 | 2018 | 123 | 0.160 |
Why?
|
Risk Assessment | 3 | 2019 | 2261 | 0.150 |
Why?
|
Case-Control Studies | 4 | 2019 | 1804 | 0.150 |
Why?
|
Disability Evaluation | 1 | 2018 | 136 | 0.150 |
Why?
|
Body Weight | 1 | 2018 | 459 | 0.150 |
Why?
|
Arthritis, Experimental | 1 | 2017 | 24 | 0.150 |
Why?
|
24,25-Dihydroxyvitamin D 3 | 1 | 2016 | 2 | 0.150 |
Why?
|
Granzymes | 1 | 2017 | 93 | 0.150 |
Why?
|
International Agencies | 1 | 2016 | 34 | 0.150 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 332 | 0.150 |
Why?
|
Blood Chemical Analysis | 1 | 2016 | 42 | 0.150 |
Why?
|
Osteocalcin | 3 | 2001 | 26 | 0.140 |
Why?
|
Biomarkers, Pharmacological | 1 | 2016 | 22 | 0.140 |
Why?
|
Administration, Intravenous | 1 | 2016 | 50 | 0.140 |
Why?
|
Pain Measurement | 1 | 2018 | 321 | 0.140 |
Why?
|
Magnetic Resonance Angiography | 1 | 2019 | 261 | 0.140 |
Why?
|
Organ Culture Techniques | 5 | 2000 | 135 | 0.140 |
Why?
|
Guideline Adherence | 1 | 2018 | 223 | 0.140 |
Why?
|
Reproducibility of Results | 3 | 2019 | 2705 | 0.140 |
Why?
|
Immunoassay | 2 | 2016 | 92 | 0.140 |
Why?
|
Extracorporeal Circulation | 2 | 2013 | 26 | 0.140 |
Why?
|
Rats | 11 | 2020 | 3990 | 0.140 |
Why?
|
Logistic Models | 2 | 2020 | 1185 | 0.140 |
Why?
|
Vascular Calcification | 1 | 2016 | 39 | 0.130 |
Why?
|
Blood Glucose | 2 | 2018 | 873 | 0.130 |
Why?
|
Collagen Type I | 1 | 2015 | 62 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 1 | 2017 | 166 | 0.130 |
Why?
|
Organ Transplantation | 1 | 1999 | 265 | 0.130 |
Why?
|
Incidence | 2 | 2014 | 1576 | 0.130 |
Why?
|
Prostaglandins | 1 | 1995 | 43 | 0.130 |
Why?
|
Acidosis, Respiratory | 1 | 1994 | 7 | 0.130 |
Why?
|
Uremia | 1 | 1994 | 15 | 0.130 |
Why?
|
Acidosis | 1 | 1994 | 55 | 0.130 |
Why?
|
Infarction | 1 | 1994 | 26 | 0.130 |
Why?
|
Sex Factors | 2 | 2013 | 1054 | 0.130 |
Why?
|
Radiology | 1 | 2017 | 194 | 0.130 |
Why?
|
Hypocalcemia | 1 | 1994 | 41 | 0.120 |
Why?
|
Parathyroid Glands | 1 | 1994 | 74 | 0.120 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 364 | 0.120 |
Why?
|
Sorption Detoxification | 1 | 2013 | 2 | 0.120 |
Why?
|
Brain Diseases | 1 | 1994 | 180 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 1673 | 0.110 |
Why?
|
Hematologic Tests | 1 | 2012 | 14 | 0.110 |
Why?
|
In Vitro Techniques | 3 | 2001 | 989 | 0.110 |
Why?
|
Colony-Forming Units Assay | 1 | 2012 | 40 | 0.110 |
Why?
|
Serum | 1 | 2012 | 25 | 0.110 |
Why?
|
Serum Amyloid P-Component | 1 | 1992 | 5 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2012 | 62 | 0.110 |
Why?
|
Cell Separation | 1 | 2012 | 196 | 0.110 |
Why?
|
Phosphate-Binding Proteins | 2 | 2010 | 9 | 0.100 |
Why?
|
Citric Acid | 2 | 2010 | 38 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2001 | 2818 | 0.100 |
Why?
|
Obesity | 1 | 2018 | 963 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2012 | 154 | 0.100 |
Why?
|
Gene Expression | 3 | 2008 | 1284 | 0.100 |
Why?
|
Wound Healing | 1 | 2013 | 344 | 0.100 |
Why?
|
Nanocomposites | 1 | 2010 | 11 | 0.100 |
Why?
|
Rats, Sprague-Dawley | 4 | 2020 | 1219 | 0.100 |
Why?
|
Absorptiometry, Photon | 3 | 2010 | 99 | 0.100 |
Why?
|
Deferoxamine | 2 | 1988 | 18 | 0.090 |
Why?
|
Protein-Energy Malnutrition | 1 | 2010 | 5 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2010 | 131 | 0.090 |
Why?
|
Models, Biological | 2 | 2008 | 1749 | 0.090 |
Why?
|
Bicarbonates | 2 | 2023 | 60 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 1991 | 151 | 0.090 |
Why?
|
Global Health | 2 | 2010 | 193 | 0.090 |
Why?
|
Receptor for Advanced Glycation End Products | 2 | 2013 | 17 | 0.090 |
Why?
|
Endothelial Cells | 1 | 2012 | 428 | 0.090 |
Why?
|
Contraindications | 1 | 2009 | 72 | 0.090 |
Why?
|
Cell Line | 3 | 2013 | 2468 | 0.090 |
Why?
|
Age Factors | 4 | 2020 | 1849 | 0.090 |
Why?
|
Pilot Projects | 2 | 2023 | 839 | 0.090 |
Why?
|
Cell Division | 2 | 2001 | 696 | 0.090 |
Why?
|
Follow-Up Studies | 3 | 2019 | 3636 | 0.080 |
Why?
|
Graft Rejection | 2 | 2006 | 1065 | 0.080 |
Why?
|
Europe | 1 | 2009 | 309 | 0.080 |
Why?
|
Neuromuscular Diseases | 1 | 1988 | 30 | 0.080 |
Why?
|
Cross-Over Studies | 1 | 2009 | 399 | 0.080 |
Why?
|
Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 4 | 0.080 |
Why?
|
Receptors, Calcitonin | 1 | 2008 | 4 | 0.080 |
Why?
|
RANK Ligand | 1 | 2008 | 8 | 0.080 |
Why?
|
Integrin beta3 | 1 | 2008 | 30 | 0.080 |
Why?
|
Physical Conditioning, Animal | 1 | 2007 | 19 | 0.080 |
Why?
|
Alzheimer Disease | 2 | 1991 | 470 | 0.080 |
Why?
|
Cyclic AMP | 2 | 1999 | 273 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2007 | 78 | 0.080 |
Why?
|
Blood-Brain Barrier | 1 | 2007 | 70 | 0.080 |
Why?
|
Proteinuria | 1 | 2008 | 107 | 0.080 |
Why?
|
Placebos | 1 | 2007 | 218 | 0.080 |
Why?
|
Isoenzymes | 1 | 2008 | 271 | 0.080 |
Why?
|
Morbidity | 1 | 2007 | 148 | 0.070 |
Why?
|
Animals, Newborn | 3 | 1994 | 510 | 0.070 |
Why?
|
Myoclonus | 1 | 1986 | 15 | 0.070 |
Why?
|
Enzyme Activation | 2 | 1999 | 692 | 0.070 |
Why?
|
Patient Selection | 1 | 2010 | 685 | 0.070 |
Why?
|
Microscopy, Electron, Scanning | 2 | 1999 | 135 | 0.070 |
Why?
|
Regression Analysis | 3 | 2010 | 596 | 0.070 |
Why?
|
Capsules | 1 | 2006 | 38 | 0.070 |
Why?
|
Antibodies | 1 | 2008 | 350 | 0.070 |
Why?
|
Down-Regulation | 2 | 2013 | 504 | 0.070 |
Why?
|
Adolescent | 3 | 2009 | 8979 | 0.070 |
Why?
|
Immunosorbent Techniques | 1 | 2005 | 13 | 0.070 |
Why?
|
Polymers | 2 | 2013 | 202 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 860 | 0.070 |
Why?
|
Radius | 1 | 2004 | 29 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2008 | 454 | 0.060 |
Why?
|
Femur Neck | 1 | 2004 | 44 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2006 | 217 | 0.060 |
Why?
|
Dementia | 1 | 1986 | 187 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 1990 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2010 | 2207 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2007 | 451 | 0.060 |
Why?
|
Alkalies | 1 | 2023 | 8 | 0.060 |
Why?
|
Seizures | 1 | 1986 | 295 | 0.060 |
Why?
|
Lumbar Vertebrae | 1 | 2004 | 148 | 0.060 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 10 | 0.060 |
Why?
|
Carpal Tunnel Syndrome | 1 | 2003 | 16 | 0.060 |
Why?
|
Medical Records | 1 | 2004 | 119 | 0.060 |
Why?
|
Joints | 1 | 2003 | 32 | 0.060 |
Why?
|
Membranes, Artificial | 1 | 2003 | 40 | 0.060 |
Why?
|
Comorbidity | 1 | 2007 | 943 | 0.060 |
Why?
|
Protein Denaturation | 1 | 2003 | 106 | 0.060 |
Why?
|
Tacrolimus | 1 | 2004 | 373 | 0.060 |
Why?
|
Carbon Dioxide | 1 | 2023 | 188 | 0.060 |
Why?
|
Brain Ischemia | 1 | 2007 | 398 | 0.060 |
Why?
|
Glucans | 1 | 2002 | 9 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2007 | 469 | 0.050 |
Why?
|
Osteomalacia | 1 | 2001 | 13 | 0.050 |
Why?
|
Glucuronidase | 2 | 1992 | 20 | 0.050 |
Why?
|
Calcitonin | 2 | 1992 | 38 | 0.050 |
Why?
|
Diuretics, Osmotic | 1 | 2001 | 2 | 0.050 |
Why?
|
Anthraquinones | 1 | 2001 | 8 | 0.050 |
Why?
|
Mannitol | 1 | 2001 | 49 | 0.050 |
Why?
|
Coloring Agents | 1 | 2001 | 64 | 0.050 |
Why?
|
Tissue Distribution | 2 | 2020 | 290 | 0.050 |
Why?
|
Kinetics | 2 | 2020 | 1513 | 0.050 |
Why?
|
Potassium Channels, Calcium-Activated | 1 | 2000 | 19 | 0.050 |
Why?
|
Sepharose | 2 | 2013 | 14 | 0.050 |
Why?
|
Vitamin B Complex | 1 | 2020 | 21 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2019 | 38 | 0.050 |
Why?
|
Staurosporine | 1 | 1999 | 33 | 0.050 |
Why?
|
Rats, Wistar | 1 | 2020 | 297 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2019 | 20 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2000 | 114 | 0.040 |
Why?
|
Polyglycolic Acid | 1 | 1999 | 9 | 0.040 |
Why?
|
Fibrosis | 1 | 2020 | 203 | 0.040 |
Why?
|
Biopolymers | 1 | 1998 | 26 | 0.040 |
Why?
|
Liver Transplantation | 2 | 1999 | 1267 | 0.040 |
Why?
|
Lactic Acid | 1 | 1999 | 90 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2019 | 185 | 0.040 |
Why?
|
Stroke | 1 | 2007 | 965 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2019 | 217 | 0.040 |
Why?
|
Drug Monitoring | 1 | 2019 | 118 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 1998 | 126 | 0.040 |
Why?
|
Hematoma | 1 | 1999 | 104 | 0.040 |
Why?
|
Rats, Inbred Strains | 2 | 1996 | 312 | 0.040 |
Why?
|
Renal Circulation | 1 | 2018 | 61 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2007 | 1753 | 0.040 |
Why?
|
Potassium Channels | 1 | 2000 | 340 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2000 | 352 | 0.040 |
Why?
|
Spin Labels | 1 | 2018 | 102 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 864 | 0.040 |
Why?
|
Reference Values | 1 | 2019 | 674 | 0.040 |
Why?
|
Healthy Volunteers | 1 | 2018 | 143 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2000 | 1981 | 0.040 |
Why?
|
Steroids | 1 | 1998 | 177 | 0.040 |
Why?
|
Transforming Growth Factor beta | 1 | 1998 | 301 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 639 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 1996 | 265 | 0.030 |
Why?
|
Prostaglandin Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2015 | 48 | 0.030 |
Why?
|
Indomethacin | 1 | 1995 | 59 | 0.030 |
Why?
|
Acute Kidney Injury | 2 | 1989 | 295 | 0.030 |
Why?
|
Radiography | 2 | 1998 | 813 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2015 | 73 | 0.030 |
Why?
|
3T3 Cells | 1 | 1994 | 94 | 0.030 |
Why?
|
Culture Media | 1 | 1994 | 147 | 0.030 |
Why?
|
Ion Transport | 1 | 1994 | 81 | 0.030 |
Why?
|
Amyloid | 1 | 1995 | 85 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1019 | 0.030 |
Why?
|
Body Mass Index | 1 | 2018 | 770 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2015 | 128 | 0.030 |
Why?
|
Patient Dropouts | 1 | 2014 | 28 | 0.030 |
Why?
|
Adsorption | 1 | 2013 | 54 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 56 | 0.030 |
Why?
|
Serum Albumin, Bovine | 1 | 2013 | 45 | 0.030 |
Why?
|
Sulfones | 1 | 2013 | 43 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2014 | 76 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2016 | 326 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1685 | 0.030 |
Why?
|
Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2013 | 63 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 1204 | 0.030 |
Why?
|
Constipation | 1 | 2014 | 63 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1994 | 493 | 0.030 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1993 | 34 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2015 | 160 | 0.030 |
Why?
|
Heart Transplantation | 1 | 1999 | 705 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 1993 | 181 | 0.030 |
Why?
|
Induction Chemotherapy | 1 | 2014 | 147 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 1994 | 212 | 0.030 |
Why?
|
Diarrhea | 1 | 2014 | 182 | 0.030 |
Why?
|
Neurons | 2 | 2000 | 1546 | 0.030 |
Why?
|
Blood Donors | 1 | 2012 | 26 | 0.030 |
Why?
|
Equipment Design | 1 | 2013 | 406 | 0.030 |
Why?
|
Nausea | 1 | 2014 | 175 | 0.030 |
Why?
|
Hip | 1 | 1992 | 18 | 0.030 |
Why?
|
Cohort Studies | 1 | 1999 | 2767 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1992 | 244 | 0.030 |
Why?
|
Shoulder | 1 | 1992 | 42 | 0.030 |
Why?
|
Behavior, Animal | 2 | 2007 | 373 | 0.030 |
Why?
|
Chlorides | 2 | 2002 | 103 | 0.030 |
Why?
|
Lysosomes | 1 | 1992 | 104 | 0.030 |
Why?
|
Rabbits | 2 | 2010 | 636 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2013 | 751 | 0.030 |
Why?
|
Hand | 1 | 1992 | 130 | 0.020 |
Why?
|
Absorption | 2 | 2002 | 25 | 0.020 |
Why?
|
Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
Durapatite | 1 | 2010 | 28 | 0.020 |
Why?
|
Materials Testing | 1 | 2010 | 91 | 0.020 |
Why?
|
Electroencephalography | 1 | 1994 | 707 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1992 | 460 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 3092 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2010 | 40 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1456 | 0.020 |
Why?
|
Heart Failure | 1 | 2019 | 1203 | 0.020 |
Why?
|
DNA | 2 | 1993 | 1294 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2010 | 193 | 0.020 |
Why?
|
Body Burden | 1 | 1988 | 9 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2010 | 268 | 0.020 |
Why?
|
Biomechanical Phenomena | 1 | 1990 | 457 | 0.020 |
Why?
|
Sarcoidosis | 1 | 1988 | 71 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 17 | 0.020 |
Why?
|
Collagen Type IV | 1 | 2007 | 24 | 0.020 |
Why?
|
Proteins | 1 | 1993 | 777 | 0.020 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2007 | 35 | 0.020 |
Why?
|
Brain Edema | 1 | 2007 | 50 | 0.020 |
Why?
|
Capillaries | 1 | 2007 | 91 | 0.020 |
Why?
|
Calcium, Dietary | 1 | 2007 | 63 | 0.020 |
Why?
|
Functional Laterality | 1 | 2007 | 201 | 0.020 |
Why?
|
Algorithms | 1 | 2015 | 1830 | 0.020 |
Why?
|
Medicare | 1 | 2010 | 406 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 916 | 0.020 |
Why?
|
Survival Analysis | 1 | 2010 | 1538 | 0.020 |
Why?
|
Blotting, Western | 1 | 2007 | 782 | 0.020 |
Why?
|
Phenotype | 1 | 2012 | 2377 | 0.020 |
Why?
|
Fluorides | 1 | 1985 | 13 | 0.020 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2005 | 14 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 879 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 1988 | 336 | 0.020 |
Why?
|
Movement | 1 | 2007 | 299 | 0.020 |
Why?
|
Sterilization | 1 | 2005 | 7 | 0.020 |
Why?
|
Drug Stability | 1 | 2005 | 48 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 1 | 1989 | 462 | 0.020 |
Why?
|
Immunoglobulin Variable Region | 1 | 2005 | 109 | 0.020 |
Why?
|
RNA | 1 | 2007 | 560 | 0.010 |
Why?
|
Titrimetry | 1 | 2003 | 15 | 0.010 |
Why?
|
Blood | 1 | 2002 | 69 | 0.010 |
Why?
|
Peritoneum | 1 | 2002 | 57 | 0.010 |
Why?
|
Aluminum Compounds | 1 | 1982 | 6 | 0.010 |
Why?
|
Urine | 1 | 2002 | 90 | 0.010 |
Why?
|
Sodium | 1 | 2002 | 341 | 0.010 |
Why?
|
Charybdotoxin | 1 | 2000 | 8 | 0.010 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2000 | 5 | 0.010 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2000 | 8 | 0.010 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channels | 1 | 2000 | 11 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 5974 | 0.010 |
Why?
|
Haplorhini | 1 | 2000 | 81 | 0.010 |
Why?
|
Protein Structure, Quaternary | 1 | 2000 | 99 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2000 | 307 | 0.010 |
Why?
|
Epitopes | 1 | 2000 | 255 | 0.010 |
Why?
|
Electrophysiology | 1 | 2000 | 401 | 0.010 |
Why?
|
Maternal-Fetal Exchange | 1 | 1979 | 76 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 646 | 0.010 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 1998 | 37 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2000 | 435 | 0.010 |
Why?
|
Choristoma | 1 | 1998 | 68 | 0.010 |
Why?
|
Drug Carriers | 1 | 1998 | 81 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 1998 | 121 | 0.010 |
Why?
|
Fetus | 1 | 1979 | 226 | 0.010 |
Why?
|
Ion Channel Gating | 1 | 2000 | 324 | 0.010 |
Why?
|
Insulin | 1 | 2002 | 1160 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2000 | 853 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1998 | 1014 | 0.010 |
Why?
|
Peptides | 1 | 2000 | 639 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 2062 | 0.010 |
Why?
|
Cations, Monovalent | 1 | 1995 | 6 | 0.010 |
Why?
|
Cations, Divalent | 1 | 1995 | 39 | 0.010 |
Why?
|
Surface Properties | 1 | 1995 | 130 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 1998 | 857 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1998 | 996 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2000 | 3030 | 0.010 |
Why?
|
Platelet Transfusion | 1 | 1995 | 14 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 1995 | 188 | 0.010 |
Why?
|
Transfusion Reaction | 1 | 1995 | 15 | 0.010 |
Why?
|
Citrates | 1 | 1995 | 28 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1995 | 82 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 1995 | 60 | 0.010 |
Why?
|
Prevalence | 1 | 1998 | 1239 | 0.010 |
Why?
|
Water Supply | 2 | 1985 | 60 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1995 | 912 | 0.010 |
Why?
|
Child | 1 | 2004 | 6926 | 0.010 |
Why?
|
Anticoagulants | 1 | 1995 | 408 | 0.010 |
Why?
|
Discriminant Analysis | 1 | 1989 | 66 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1995 | 2378 | 0.010 |
Why?
|
Pregnancy Trimester, Second | 1 | 1988 | 66 | 0.010 |
Why?
|
Pregnancy | 2 | 1988 | 2893 | 0.000 |
Why?
|
Computers | 1 | 1985 | 112 | 0.000 |
Why?
|
Binding Sites | 1 | 1985 | 1098 | 0.000 |
Why?
|
Brain | 2 | 1985 | 2216 | 0.000 |
Why?
|
Avoidance Learning | 1 | 1982 | 16 | 0.000 |
Why?
|
Extinction, Psychological | 1 | 1982 | 19 | 0.000 |
Why?
|
Rats, Inbred F344 | 1 | 1982 | 156 | 0.000 |
Why?
|
Michigan | 1 | 1981 | 52 | 0.000 |
Why?
|
Motor Skills | 1 | 1982 | 71 | 0.000 |
Why?
|
Brain Chemistry | 1 | 1981 | 121 | 0.000 |
Why?
|
Dogs | 1 | 1981 | 685 | 0.000 |
Why?
|
Motor Activity | 1 | 1982 | 327 | 0.000 |
Why?
|
Teratogens | 1 | 1979 | 13 | 0.000 |
Why?
|
Fetal Death | 1 | 1979 | 56 | 0.000 |
Why?
|
Drug Synergism | 1 | 1979 | 303 | 0.000 |
Why?
|
Neutron Activation Analysis | 1 | 1978 | 2 | 0.000 |
Why?
|
Spectrophotometry, Atomic | 1 | 1978 | 12 | 0.000 |
Why?
|
Gestational Age | 1 | 1979 | 311 | 0.000 |
Why?
|
Mental Disorders | 1 | 1978 | 371 | 0.000 |
Why?
|